Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).

scientific article published on 13 December 2015

Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.EJCA.2015.09.018
P8608Fatcat IDrelease_6mjrokjiyfcx7edn3w3jed4dk4
P698PubMed publication ID26693898
P5875ResearchGate publication ID286904328

P50authorJeong Hoon LeeQ39185931
Hwoon-Yong JungQ57766691
P2093author name stringYoon-Koo Kang
Young Soo Park
Sook Ryun Park
Baek-Yeol Ryoo
Chang Gok Woo
Min-Hee Ryu
Gin Hyug Lee
P304page(s)42-50
P577publication date2015-12-13
P1433published inEuropean Journal of CancerQ332260
P1476titleExtra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).
P478volume53

Reverse relations

cites work (P2860)
Q40619773Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications
Q87944884Clinicopathological features and endoscopic findings of HER2-positive gastric cancer
Q92905048Correlation of HER2, MDM2, c-MYC, c-MET, and TP53 Copy Number Alterations in Circulating Tumor Cells with Tissue in Gastric Cancer Patients: A Pilot Study
Q64076253Detection of (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort
Q50642054Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
Q50433440Discordance Rate of HER2 Status in Primary Gastric Cancer and Synchronous Lymph Node Metastases: Its Impact on Therapeutic Decision and Clinical Management
Q93059944Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions
Q92644985Elevated level of Vav1 was correlated with advanced biological behavior and poor prognosis in patients with gastric cancer
Q89683058Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
Q99622843Gastric cancer
Q46129222Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.
Q39080349HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Q26741253HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice
Q92685589HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
Q51541370HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.
Q39174711HER2 testing in gastric cancer: results of a German expert meeting
Q50160878Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2-positive gastric cancer patients
Q58553403Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)
Q28077666Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
Q55039208Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression.
Q53073585[HER2 testing in gastric cancer : Results of a meeting of German experts].

Search more.